Reply by Authors
Justin T. Matulay(Levine Cancer Institute), Ashish M. Kamat(The University of Texas MD Anderson Cancer Center), Patrick J. Hensley(University of Kentucky), Roger Li(Unknown), Nathan A. Brooks(Eli Lilly (United States)), Vikram M. Narayan(Emory University), Neema Navai(The University of Texas MD Anderson Cancer Center), H. Barton Grossman(The University of Texas MD Anderson Cancer Center), Colin P. Dinney(The University of Texas MD Anderson Cancer Center)
Cited by 0
Related Papers
Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer
|New England Journal of Medicine|2003|2.6k
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study
|The Lancet Oncology|2021|532
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial
|The Lancet Oncology|2020|459
A Comparison of Hexaminolevulinate Fluorescence Cystoscopy and White Light Cystoscopy for the Detection of Carcinoma In Situ in Patients With Bladder Cancer: A Phase III, Multicenter Study
|The Journal of Urology|2007|314
Multicenter Assessment of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer
|European Urology|2014|297